Organovo Holdings, Inc. (ONVO)
NASDAQ: ONVO · IEX Real-Time Price · USD
0.605
+0.014 (2.42%)
Jul 22, 2024, 9:54 AM EDT - Market open
Organovo Holdings Employees
As of March 31, 2024, Organovo Holdings had 20 total employees, including 12 full-time and 8 part-time employees. The number of employees decreased by 4 or -16.67% compared to the previous year.
Employees
20
Change (1Y)
-4
Growth (1Y)
-16.67%
Revenue / Employee
$5,450
Profits / Employee
-$733,550
Market Cap
9.01M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Syra Health | 162 |
Zhongchao | 142 |
Vivos Therapeutics | 123 |
iCoreConnect | 70 |
Molecular Templates | 62 |
Kineta | 13 |
NLS Pharmaceutics AG | 7 |
Virpax Pharmaceuticals | 7 |
ONVO News
- 4 days ago - Top 3 Health Care Stocks Which Could Rescue Your Portfolio In July - Benzinga
- 6 days ago - Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis - GlobeNewsWire
- 2 months ago - Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease - GlobeNewsWire
- 2 months ago - Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024) - GlobeNewsWire
- 2 months ago - Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering - GlobeNewsWire
- 3 months ago - Organovo's fatty liver disease drug meets main goal in mid-stage study - Reuters
- 3 months ago - Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo - GlobeNewsWire
- 6 months ago - Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn's and Colitis Congress - GlobeNewsWire